What’s happening with 23andMe? Mass layoffs and restructuring are the latest blow for the embattled DNA-testing company
The once-high-flying firm has been beset by challenges since going public via a SPAC merger in 2021. Here’s the latest.
DNA-testing site 23andMe to lay off 40% of its workers
The struggling genetic testing company 23andMe says it will cut 40% of its workforce, or 200 jobs, as it fights for ...
The Hindu21h
If 23andMe goes bust, what happens to its DNA database?
But what can customers of 23andMe themselves do to make sure their highly personal genetic data is protected? And should we ...
23andMe says there’s ‘substantial doubt’ it can stay in business
23andMe Holding Co.’s stock turned down early Tuesday, after the DNA-testing company reported its latest quarterly loss, ...
Yahoo1d
What happens to customer data as 23andMe goes out of business?
Millions of people have sent their DNA to be analyzed by 23andMe in order to learn their genealogy and risk for certain ...
23andMe Lays Off 40% of Its Workforce as Company Spirals
The genetic testing company 23andMe announced it was laying off more than 200 employees, or roughly 40% of its entire ...
23andMe to slash 40% of its workforce, end therapeutics program to cut costs
DNA-testing company 23andMe Holding Co. will slash its workforce by about 40% and discontinue its therapeutics program as ...
Yahoo2d
23andMe is falling apart
23andMe (ME), the company that popularized at-home DNA tests, announced on Tuesday that its sales took a hit during its ...
FierceBiotech3d
23andMe shutters cancer drug research programs, lays off 40% of staff
23andMe is shutting down its therapeutics development division and plans to seek out buyers to find a new home for its ...
newsbytesapp.com2d
DNA-testing site 23andMe is slashing its workforce by 40%
23andMe's woes were further exacerbated by a data breach last year, wherein hackers gained access to personal information ...
PCMag on MSN2d
23andMe to Cut 40% of Its Staff Amid Grim Financials
The DNA testing kit company is also discontinuing new developments to its therapeutics program, which has been focused on ...